AR068901A1 - Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos - Google Patents
Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivosInfo
- Publication number
- AR068901A1 AR068901A1 ARP080104523A ARP080104523A AR068901A1 AR 068901 A1 AR068901 A1 AR 068901A1 AR P080104523 A ARP080104523 A AR P080104523A AR P080104523 A ARP080104523 A AR P080104523A AR 068901 A1 AR068901 A1 AR 068901A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- treatment
- albumin
- cognitive disorders
- therapeutic
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 4
- 102000008100 Human Serum Albumin Human genes 0.000 title abstract 2
- 108091006905 Human Serum Albumin Proteins 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- 102000009027 Albumins Human genes 0.000 abstract 3
- 108010088751 Albumins Proteins 0.000 abstract 3
- 238000001990 intravenous administration Methods 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente se basa en la utilizacion de albumina humana terapéutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos, en la que el modelo de administracion del medicamento comprende la administracion al paciente de un mínimo de tres veces sucesivas, de una cantidad terapéuticamente efectiva de albumina terapéutica humana mediante recambio plasmático y/o perfusion intravenosa, sin dependencia del contenido de Abeta en sangre del paciente. Reivindicacion 2: Utilizacion, segun la reivindicacion 1, caracterizada porque el medicamento adopta la forma de solucion para recambio plasmático. Reivindicacion 3: Utilizacion, segun la reivindicacion 1, caracterizada porque el medicamento adopta la forma de solucion para utilizacion intravenosa. Reivindicacion 6: Utilizacion, segun las reivindicaciones anteriores, caracterizada porque la albumina utilizada tiene una capacidad de enlace superior al de la albumina terapéutica formulada segun Farmacopea Europea.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702831A ES2332846B1 (es) | 2007-10-26 | 2007-10-26 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068901A1 true AR068901A1 (es) | 2009-12-16 |
Family
ID=40583637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104523A AR068901A1 (es) | 2007-10-26 | 2008-10-17 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7851446B2 (es) |
| EP (1) | EP2111868B1 (es) |
| JP (1) | JP5437619B2 (es) |
| CN (1) | CN101417123B (es) |
| AR (1) | AR068901A1 (es) |
| AU (1) | AU2008233025B8 (es) |
| BR (1) | BRPI0804623B8 (es) |
| CA (1) | CA2641830C (es) |
| CL (1) | CL2008003133A1 (es) |
| ES (2) | ES2332846B1 (es) |
| HK (1) | HK1126689A1 (es) |
| MX (1) | MX2008013635A (es) |
| NZ (1) | NZ572131A (es) |
| PL (1) | PL2111868T3 (es) |
| PT (1) | PT2111868E (es) |
| RU (1) | RU2414925C2 (es) |
| UY (1) | UY31418A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10112000B2 (en) | 2010-07-08 | 2018-10-30 | Asahi Kasei Medical Co., Ltd. | Method for reducing amyloid beta concentration in blood |
| KR20220107322A (ko) * | 2016-08-18 | 2022-08-02 | 알카헤스트 인코포레이티드 | 노화-관련된 인지 장애 치료제로서의 혈장 분획 |
| US11103530B2 (en) | 2018-10-26 | 2021-08-31 | Alkahest, Inc. | Methods of improving or accelerating postoperative recovery |
| EA039316B1 (ru) * | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| UA127828C2 (uk) | 2017-04-26 | 2024-01-17 | Алкахест, Інк. | Спосіб застосування фракції білків плазми крові для лікування когнітивних порушень |
| MA53182A (fr) * | 2018-07-20 | 2021-05-26 | Alkahest Inc | Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits à base de plasma sanguin |
| EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
| CN116406374A (zh) | 2020-10-30 | 2023-07-07 | 深圳普罗吉医药科技有限公司 | 人血清白蛋白在治疗疾病中的应用 |
| BR112023020972A2 (pt) * | 2021-04-30 | 2023-12-12 | Grifols Worldwide Operations Ltd | Uso de troca de plasma terapêutico e baixo volume de troca de plasma para o tratamento de uma diminuição cognitiva |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612137A1 (de) | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | Steriles plasmaaustauschmittel |
| US5112298A (en) | 1990-06-25 | 1992-05-12 | Baxter International Inc. | Apheresis method and device |
| US5178603A (en) | 1990-07-24 | 1993-01-12 | Baxter International, Inc. | Blood extraction and reinfusion flow control system and method |
| US6627151B1 (en) * | 1997-06-13 | 2003-09-30 | Helmut Borberg | Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion |
| JP4851676B2 (ja) | 2000-05-23 | 2012-01-11 | ザ ユニバーシティ オブ サザン カリフォルニア | アルツハイマー病におけるｌｄｌレセプタータンパク質１（ｌｒｐ−１）の役割 |
| WO2002078670A1 (en) * | 2001-03-02 | 2002-10-10 | Neuron Therapeutics, Inc. | Neuroprotectants formulations and methods |
| WO2003051374A2 (en) | 2001-12-17 | 2003-06-26 | New York State Office Of Mental Health | SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
| MXPA05003607A (es) | 2002-10-04 | 2005-11-17 | Prana Biotechnology Ltd | Compuestos neurologicamente activos. |
| WO2004056318A2 (en) * | 2002-12-19 | 2004-07-08 | New York University | Method for treating amyloid disease |
| CN100384471C (zh) | 2003-02-13 | 2008-04-30 | 奥克塔法马股份有限公司 | 白蛋白溶液及其制备方法 |
| KR20060040676A (ko) | 2003-07-11 | 2006-05-10 | 미리어드 제네틱스, 인크. | 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형 |
| AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| US7436304B1 (en) | 2005-07-19 | 2008-10-14 | Visible Assets, Inc | Evidence tracking |
-
2007
- 2007-10-26 ES ES200702831A patent/ES2332846B1/es not_active Expired - Fee Related
-
2008
- 2008-10-17 NZ NZ572131A patent/NZ572131A/en unknown
- 2008-10-17 RU RU2008141076/15A patent/RU2414925C2/ru active
- 2008-10-17 AR ARP080104523A patent/AR068901A1/es unknown
- 2008-10-22 ES ES08380301T patent/ES2428698T3/es active Active
- 2008-10-22 PL PL08380301T patent/PL2111868T3/pl unknown
- 2008-10-22 PT PT83803015T patent/PT2111868E/pt unknown
- 2008-10-22 EP EP08380301.5A patent/EP2111868B1/en active Active
- 2008-10-23 CL CL2008003133A patent/CL2008003133A1/es unknown
- 2008-10-23 MX MX2008013635A patent/MX2008013635A/es active IP Right Grant
- 2008-10-23 CN CN2008101705786A patent/CN101417123B/zh active Active
- 2008-10-23 BR BRPI0804623A patent/BRPI0804623B8/pt active IP Right Grant
- 2008-10-23 UY UY31418A patent/UY31418A1/es not_active Application Discontinuation
- 2008-10-24 CA CA2641830A patent/CA2641830C/en active Active
- 2008-10-24 JP JP2008274076A patent/JP5437619B2/ja active Active
- 2008-10-24 US US12/257,814 patent/US7851446B2/en active Active
- 2008-10-24 AU AU2008233025A patent/AU2008233025B8/en active Active
-
2009
- 2009-07-02 HK HK09105923.2A patent/HK1126689A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY31418A1 (es) | 2009-05-29 |
| PL2111868T3 (pl) | 2014-01-31 |
| JP2009108059A (ja) | 2009-05-21 |
| EP2111868B1 (en) | 2013-08-21 |
| CA2641830C (en) | 2013-07-16 |
| CL2008003133A1 (es) | 2009-08-07 |
| BRPI0804623B8 (pt) | 2021-05-25 |
| PT2111868E (pt) | 2013-10-17 |
| JP5437619B2 (ja) | 2014-03-12 |
| HK1126689A1 (en) | 2009-09-11 |
| CN101417123A (zh) | 2009-04-29 |
| US7851446B2 (en) | 2010-12-14 |
| NZ572131A (en) | 2010-06-25 |
| CA2641830A1 (en) | 2009-04-26 |
| RU2008141076A (ru) | 2010-04-27 |
| ES2332846B1 (es) | 2010-07-08 |
| CN101417123B (zh) | 2012-06-27 |
| US20090111740A1 (en) | 2009-04-30 |
| ES2332846A1 (es) | 2010-02-12 |
| BRPI0804623A2 (pt) | 2009-06-30 |
| BRPI0804623B1 (pt) | 2020-02-11 |
| AU2008233025B2 (en) | 2013-06-27 |
| RU2414925C2 (ru) | 2011-03-27 |
| MX2008013635A (es) | 2009-05-11 |
| EP2111868A1 (en) | 2009-10-28 |
| AU2008233025B8 (en) | 2013-07-25 |
| ES2428698T3 (es) | 2013-11-08 |
| AU2008233025A1 (en) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068901A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| Zarocostas | WHO recommends early antiviral treatment for at risk groups with suspected swine flu | |
| JP2013155188A5 (es) | ||
| BRPI0820800A2 (pt) | Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| JP2014515408A5 (es) | ||
| WO2008067991A3 (en) | Skin-friendly drug complexes for transdermal administration | |
| JP2013541583A5 (es) | ||
| JP2012524112A5 (es) | ||
| JP2010518164A5 (es) | ||
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| ECSP077843A (es) | Tratamiento o prevención del prurito | |
| CN114588164A (zh) | 瑞马唑仑在预防围术期低体温和寒战中的应用 | |
| CN105213519A (zh) | 一种治疗腰椎间盘突出、骨质增生的药物及其制备方法 | |
| Rajput et al. | Randomized clinical trial to evaluate the efficacy of Ashtamangal Ghrita oral and Nasya in the management of cerebral palsy | |
| Mahmoodiyeh et al. | Comparison between infusion pumps: Fentanyl/ketamine and fentanyl/paracetamol in pain control following tight and leg surgeries | |
| JP2016504361A5 (es) | ||
| Almomani | The effect of ketamine on blood pressure, heart rate, respiratory rate and intraocular pressure in patients undergoing ocular procedures | |
| CN104784332B (zh) | 一种治疗慢性尿路感染的药剂的制备方法 | |
| Lintner | Metaxalone overdose | |
| Kharchenko et al. | Development of gels anti-inflammatory and analgesic action for the treatment of sports injuries | |
| JP2015512439A5 (es) | ||
| Lee et al. | A Case report of menopausal disorder patient who had back pain treated with Kamisoyosan-gamibang | |
| Ilchenko et al. | Prospects of aliskiren usage in diabetic patients type 2 as antihypertensive therapy | |
| Tiwari et al. | The significant role of nasya in the management of avabahuka |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |